CAG
MNTA

Csenge Advisory Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Csenge Advisory Group’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-26
Closed – – 1726
2018
Q3 		$0 Buy
+26
New +$703 ﹤0.01% 1808

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Csenge Advisory Group's MNTA Position: Q4 2018 in Review

Csenge Advisory Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2018, closing a stake of 26 shares.

Csenge Advisory Group first reported a position in MNTA in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 158 funds tracked by Wall St. Rank hold MNTA as of Q4 2018.

  • Csenge Advisory Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Csenge Advisory Group sold 26 Momenta Pharmaceuticals, Inc. shares in Q4 2018.
  • Csenge Advisory Group first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
  • Csenge Advisory Group's Momenta Pharmaceuticals, Inc. position peaked at $0 in Q3 2018.
  • 158 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2018.

Based on Csenge Advisory Group's 13F filing for Q4 2018, filed 7 Feb 2019.